
SGMT Stock Forecast & Price Target
SGMT Analyst Ratings
Bulls say
Sagimet Biosciences is set to benefit from its licensing agreement for denifanstat in Greater China, with the potential for significant milestone payments and royalties. The drug's high efficacy in China may drive its success, and the upcoming AURORA study results are highly anticipated as a catalyst for the company's potential peak revenue of $2.2 billion. With enough cash to fund operations for about a year and the potential for approval in Greater China by 2026-2027, Sagimet's drug is poised to disrupt the acne market as a preferred treatment option for moderate-to-severe patients, competing with the highly effective but restricted isotretinoin.
Bears say
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing FASN inhibitors for various diseases including MASH, acne, and certain forms of cancer. Despite promising results from its drug candidate, Denifanstat, potential competition and the eventual expiration of exclusivity patents pose a risk to its potential success. The success of the drug hinges on passing all three FDA co-primary endpoints and the presentation of additional efficacy details at EADV. The company faces pressure to deliver strong sales in a competitive market, with recent launches of similar products showing potential growth.
This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SGMT Analyst Forecast & Price Prediction
Start investing in SGMT
Order type
Buy in
Order amount
Est. shares
0 shares